|
| |
DyaxDyax is developing and commercializing new products for the pharmaceutical and biopharmaceutical industries. We discover and develop products using Dyax's two technology platforms:
Phage Display Binding Technology
Rapid identification of proteins, peptides and human antibodies for all applications
High throughput discovery of high affinity target-binding molecules
Greater diversity than any combinatorial chemistry method
Separations Products Platform
Chromatography systems and products sold under the Biotage™ tradename, providing timely, cost-effective solutions to the changing purification needs of the biopharmaceutical and traditional pharmaceuticals industries.
| Contact Details: |
| 300 Technology Square |
| Cambridge |
| MA |
| 02139 |
| United States of America |
| Tel: | 617 225 2500 |
| Fax: | 617 225 2501 |
| Email: | thrapeutics@dyax.com |
| WWW: | www.dyax.com/
|
|
Loading...
|
Recent Publications by Dyax: |  |
The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification process.
Increased upstream productivity and the continuous pressure to deliver... | 13th October, 2009
| Process Sciences and Discovery Research, 300 Technology Square, Dyax
| J Chromatogr A. 2009 Sep 23.
DOI Direct Link |
Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases.
KLK1 (tissue kallikrein 1) is a member of the tissue kallikrein family of... | 11th September, 2009
| Discovery Research, Dyax Corp., 300 Technology Square, Cambridge, MA
| Biochem J. 2009 Aug 13;422(2):383-92.
DOI Direct Link |
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.
Inhibition of specific matrix metalloproteinases (MMP) is an attractive... | 25th March, 2009
| Dyax Corp, Cambridge,
| Cancer Res. 2009 Feb 15;69(4):1517-26. Epub 2009 Feb 10.
DOI Direct Link |
Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates.
A number of small charged carbohydrate moieties have been associated with... | 22nd January, 2009
| Dyax SA, Liege, Belgium.
| J Immunol. 2008 Nov 1;181(9):6213-21.
|
Screening isolates from antibody phage-display libraries.
Antibody phage display, coupled with automated screening, facilitates and... | 3rd October, 2008
| Dyax Corp., 300 Technology Square, Cambridge, MA 02139, USA.
| Drug Discov Today. 2008 Apr;13(7-8):318-24. Epub 2007 Nov 26.
DOI Direct Link |
→View more Dyax research publications. |
Press Releases on Dyax:
|
 |
| Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight |
5th November, 2009 |
Reportlinker |
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis |
4th May, 2009 |
Fovea Pharmaceuticals |
PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients
|
| Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker |
16th April, 2009 |
Athera Biotechnologies |
STOCKHOLM, Sweden, April 16 /PRNewswire/ -- Athera Biotechnologies AB, an
atherosclerosis R&D company developing novel products for treatment and
prevention of cardiovascular disease (CVD),
|
| Affitech Strengthens Patent Position on its Phagemid Antibody Screening Technology in Europe |
2nd April, 2009 |
Affitech AS |
OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 472 times since April 2007, the link to the organisation's website has been followed 62 times Recent Search Terms used to find this page: dyax pharma | S.A. dyax liege 2009 | S.A. dyax liege 2009 | AZ APPLICATIONS dyax | technology square cambridge ma | dyax | 300 technology square cambridge ma | 300 technology square cambridge ma | Dyax Pharmaceutical | . Search for more companies in Cambridge Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Dyax |
